title: A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice.
abstract: OBJECTIVE
  The CD40-CD154 interaction directs autoimmune inflammation. Therefore, a long-standing goal in the treatment of autoimmune disease has been to control the formation of that interaction and thereby prevent destructive inflammation. Antibodies blocking CD154 are successful in mouse models of autoimmune disease but, while promising when used in humans, unfortunate thrombotic events have occurred, forcing the termination of those studies.
  
  
  METHODS
  To address the clinical problem of thrombotic events caused by anti-CD154 antibody treatment, we created a series of small peptides based on the CD154 domain that interacts with CD40 and tested the ability of these peptides to target CD40 and prevent type 1 diabetes in NOD mice.
  
  
  RESULTS
  We identified a lead candidate, the 15-mer KGYY15 peptide, which specifically targets CD40-positive cells in a size- and sequence-dependent manner. It is highly efficient in preventing hyperglycaemia in NOD mice that spontaneously develop type 1 diabetes. Importantly, KGYY15 can also reverse new-onset hyperglycaemia. KGYY15 is well tolerated and functions to control the cytokine profile of culprit Th40 effector T cells. The KGYY15 peptide is 87% homologous to the human sequence, suggesting that it is an important candidate for translational studies.
  
  
  CONCLUSIONS
  Peptide KGYY15 constitutes a viable therapeutic option to antibody therapy in targeting the CD40-CD154 interaction in type 1 diabetes. Given the involvement of CD40 in autoimmunity in general, it will also be important to evaluate KGYY15 in the treatment of other autoimmune diseases. This alternative therapeutic approach opens new avenues of exploration in targeting receptor-ligand interactions.
authors.affiliation: Webb-Waring Center, University of Colorado Denver, C322, 12850 East Montview Boulevard, Aurora, CO, USA.
authors.forename: Gisela M
authors.initials: GM
authors.lastname: Vaitaitis
authors.forename: Michael H
authors.initials: MH
authors.lastname: Olmstead
authors.forename: Dan M
authors.initials: DM
authors.lastname: Waid
authors.forename: Jessica R
authors.initials: JR
authors.lastname: Carter
authors.forename: David H
authors.initials: DH
authors.lastname: Wagner
mesh_terms: D000818:Animals; D015551:Autoimmunity / Q000276:immunology; D019013:CD40 Antigens / Q000037:antagonists & inhibitors* / Q000276:immunology; D023201:CD40 Ligand / Q000037:antagonists & inhibitors* / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000276:immunology*; D051379:Mice; D016688:Mice, Inbred NOD; D010455:Peptides / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D019013:CD40 Antigens; D010455:Peptides; D023201:CD40 Ligand
references.citation: J Immunol. 2002 Feb 15;168(4):2046-53
references.pmid: 11823542
references.citation: J Immunol. 2001 Jan 1;166(1):353-60
references.pmid: 11123312
references.citation: Cell Mol Immunol. 2013 Nov;10(6):483-9
references.pmid: 24037181
references.citation: J Immunol. 2003 Apr 1;170(7):3455-9
references.pmid: 12646605
references.citation: Clin Immunol. 2007 Aug;124(2):138-48
references.pmid: 17560173
references.citation: J Mol Med (Berl). 2009 Feb;87(2):181-97
references.pmid: 18985310
references.citation: J Autoimmun. 2008 Dec;31(4):385-92
references.pmid: 18951762
references.citation: J Clin Invest. 1999 Jan;103(2):281-90
references.pmid: 9916140
references.citation: PLoS One. 2012;7(6):e38708
references.pmid: 22685601
references.citation: Science. 1993 Sep 3;261(5126):1328-30
references.pmid: 7689748
references.citation: Nature. 1992 May 7;357(6373):80-2
references.pmid: 1374165
references.citation: Biochemistry. 1995 Aug 8;34(31):9884-92
references.pmid: 7543281
references.citation: J Rheumatol. 2001 Jan;28(1):95-101
references.pmid: 11196549
references.citation: Curr Opin Immunol. 1997 Jun;9(3):330-7
references.pmid: 9203418
references.citation: Biochem Pharmacol. 2009 Apr 1;77(7):1236-45
references.pmid: 19283894
references.citation: Invest New Drugs. 2002 May;20(2):209-19
references.pmid: 12099581
references.citation: J Leukoc Biol. 2008 Aug;84(2):431-9
references.pmid: 18469093
references.citation: Expert Rev Neurother. 2012 Apr;12(4):371-84
references.pmid: 22449210
references.citation: J Leukoc Biol. 2002 Jul;72(1):19-23
references.pmid: 12101258
references.citation: J Immunol. 2009 Aug 1;183(3):1851-61
references.pmid: 19596991
references.citation: Eur J Immunol. 1994 Dec;24(12):3148-54
references.pmid: 7528671
references.citation: J Autoimmun. 2001 Feb;16(1):37-46
references.pmid: 11221995
references.citation: Curr Opin Mol Ther. 2008 Oct;10(5):516-25
references.pmid: 18830927
references.citation: Autoimmunity. 2004 Sep-Nov;37(6-7):457-64
references.pmid: 15621572
references.citation: J Pept Res. 2005 Jun;65(6):591-604
references.pmid: 15885118
references.citation: Diabetologia. 2009 Jun;52(6):997-9
references.pmid: 19360393
references.citation: BJOG. 2011 Oct;118(11):1349-56
references.pmid: 21668768
references.citation: Eur J Immunol. 2004 May;34(5):1488-97
references.pmid: 15114683
references.citation: J Mol Med (Berl). 2009 Nov;87(11):1133-43
references.pmid: 19707732
references.citation: J Biol Chem. 2012 May 25;287(22):18055-66
references.pmid: 22461623
references.citation: Biochemistry. 1995 Feb 14;34(6):1833-44
references.pmid: 7531493
references.citation: Immunity. 2003 Dec;19(6):877-89
references.pmid: 14670304
references.citation: Arthritis Rheum. 2003 Mar;48(3):719-27
references.pmid: 12632425
references.citation: Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3782-7
references.pmid: 11891296
references.citation: Mol Immunol. 2010 Aug;47(14):2303-13
references.pmid: 20646763
references.citation: J Immunol. 2007 Jan 15;178(2):671-82
references.pmid: 17202327
references.citation: PLoS One. 2008 Apr 30;3(4):e2076
references.pmid: 18446238
references.citation: Int J Mol Med. 1999 Sep;4(3):231-42
references.pmid: 10425271
references.citation: Mod Rheumatol. 2005;15(6):423-6
references.pmid: 17029106
references.citation: Arthritis Rheum. 2003 Sep;48(9):2541-54
references.pmid: 13130474
references.citation: Immunity. 2002 May;16(5):719-32
references.pmid: 12049723
references.citation: Rev Immunogenet. 2000;2(1):74-80
references.pmid: 11324695
references.citation: J Biol Chem. 2002 Apr 19;277(16):13796-803
references.pmid: 11830590
references.citation: J Immunol. 1997 Nov 1;159(9):4620-7
references.pmid: 9379064
references.citation: Lupus. 2004;13(5):391-7
references.pmid: 15230298